PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience: E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy. Bleeding, Thrombosis and Vascular Biology, [S. l.], v. 4, n. s1, 2025. DOI: 10.4081/btvb.2025.313. Disponível em: https://www.btvb.org/btvb/article/view/313. Acesso em: 6 aug. 2025.